A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...
Zacks Investment Research on MSN1d
AXSM Stock Down on Top-Line Data From Depression Study on SolriamfetolAxsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...
Investor's Business Daily on MSN2d
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A WeekAxsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.
Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...
Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major ...
After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...
Under the terms of the settlement agreement, Axsome will grant Hikma a license to sell its generic version of Sunosi beginning on or after September 1, 2040, if pediatric exclusivity is granted ...
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...
Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ ... the results of a phase 3 trial of solriamfetol (brand name Sunosi) in major depressive disorder (MDD). The trial was somewhat ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback